journal article·2025-09-02Open access

Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal–Photodynamic–Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells

Qing Pan, Wei Wu, Doudou Jing, Wei Huang, Yongzhi Cui, Zhicai Zhang, Zengwu Shao, Hongzhi Hu, Wenbo Yang

ACS Nano· Volume 19· Issue 34

Abstract

High Resolution Image Download MS PowerPoint Slide Osteosarcoma is a highly aggressive bone tumor with limited treatment options because of its drug resistance and tumor heterogeneity. In this study, we developed a multifunctional nanomaterial, P-Fe 3 O 4 @Pal@HM, combining porous Fe 3 O 4 nanoparticles, the DNA intercalator palmatine, and a hybrid membrane coating derived from osteosarcoma cells and tumor-associated endothelial cells. The Fe 3 O 4 core facilitates a Fenton-like reaction, generating reactive oxygen species (ROS) to enhance DNA damage, whereas palmatine (Pal) inhibits RRM2 (ribonucleotide reductase regulatory subunit M2) expression, blocking DNA repair and inducing apoptosis. The hybrid membrane coating provides precise targeting of both tumor and endothelial cells, thus addressing the challenge of tumor heterogeneity. Under low-temperature photothermal conditions, the Fenton-like reaction is further enhanced, boosting ROS production and increasing cytotoxicity. This nanomaterial also modulates the immune microenvironment by promoting M1 macrophage polarization, thereby amplifying the antitumor immune response. P-Fe 3 O 4 @Pal@HM demonstrated superior therapeutic efficacy to conventional treatments, significantly reducing tumor volume and inducing apoptosis with minimal toxicity to normal tissues. This innovative approach offers a promising strategy to overcome drug resistance, improve tumor targeting, and enhance treatment outcomes in osteosarcoma. The multifunctional design of P-Fe 3 O 4 @Pal@HM highlights its potential as an advanced therapeutic platform in osteosarcoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics, Union Hospital, Tongji Medical College

Huazhong University of Science and Technology

Department of Orthopaedics

Shanxi Medical University Second Affiliated Hospital

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (62)

Show source-provided references
1. 10.3390/jmp402001110.3390/jmp4020011 ↗
2. 10.3390/cells1001017210.3390/cells10010172 ↗
3. 10.3389/fimmu.2022.90755010.3389/fimmu.2022.907550 ↗
4. 10.3390/ijms2115520710.3390/ijms21155207 ↗
5. 10.1038/s41698-025-00896-810.1038/s41698-025-00896-8 ↗
6. 10.3389/fimmu.2024.136787510.3389/fimmu.2024.1367875 ↗
7. 10.18632/oncotarget.2595410.18632/oncotarget.25954 ↗
8. 10.7150/thno.6942410.7150/thno.69424 ↗
9. 10.3389/fphar.2019.0153110.3389/fphar.2019.01531 ↗
10. 10.3390/cancers1304068310.3390/cancers13040683 ↗
11. 10.20517/cdr.2022.1810.20517/cdr.2022.18 ↗
12. 10.1158/0008-5472.CAN-19-379110.1158/0008-5472.CAN-19-3791 ↗
13. 10.1016/j.ejps.2024.10693910.1016/j.ejps.2024.106939 ↗
14. 10.1038/cddis.2017.47110.1038/cddis.2017.471 ↗
15. 10.1021/acs.jpclett.4c0272110.1021/acs.jpclett.4c02721 ↗
16. 10.1016/j.jconrel.2022.08.01110.1016/j.jconrel.2022.08.011 ↗
17. 10.1016/j.copbio.2023.10301310.1016/j.copbio.2023.103013 ↗
18. 10.1007/s12274-022-5303-510.1007/s12274-022-5303-5 ↗
19. 10.2174/138955752366623020314564510.2174/1389557523666230203145645 ↗
20. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
21. 10.3389/fcell.2022.84405010.3389/fcell.2022.844050 ↗
22. 10.1186/s13045-024-01598-710.1186/s13045-024-01598-7 ↗
23. 10.3389/fonc.2020.58658010.3389/fonc.2020.586580 ↗
24. 10.1186/s12943-023-01871-210.1186/s12943-023-01871-2 ↗
25. 10.1016/j.ccell.2022.08.01210.1016/j.ccell.2022.08.012 ↗
26. 10.1038/s41698-024-00522-z10.1038/s41698-024-00522-z ↗
27. 10.1038/s41568-023-00591-510.1038/s41568-023-00591-5 ↗
28. 10.1016/j.biopha.2020.11099610.1016/j.biopha.2020.110996 ↗
29. 10.3390/cancers301135110.3390/cancers3011351 ↗
30. 10.1002/advs.20241042710.1002/advs.202410427 ↗
31. 10.1093/neuonc/noad179.042110.1093/neuonc/noad179.0421 ↗
32. 10.3389/fmolb.2022.83800610.3389/fmolb.2022.838006 ↗
33. 10.3390/pharmaceutics1509233710.3390/pharmaceutics15092337 ↗
34. 10.1016/j.cej.2024.14976110.1016/j.cej.2024.149761 ↗
35. 10.1039/D1SC05482A10.1039/D1SC05482A ↗
36. 10.3390/ijms2404324910.3390/ijms24043249 ↗
37. 10.1002/EXP.2021000510.1002/EXP.20210005 ↗
38. 10.1186/s40169-019-0224-y10.1186/s40169-019-0224-y ↗
39. 10.2147/JIR.S41816610.2147/JIR.S418166 ↗
40. 10.7717/peerj.1581410.7717/peerj.15814 ↗
41. 10.1186/s13059-014-0550-810.1186/s13059-014-0550-8 ↗
42. 10.1038/s41467-020-20059-610.1038/s41467-020-20059-6 ↗
43. 10.1089/omi.2011.011810.1089/omi.2011.0118 ↗
44. 10.1073/pnas.050658010210.1073/pnas.0506580102 ↗
45. 10.1038/ng118010.1038/ng1180 ↗
46. 10.1093/bioinformatics/btr26010.1093/bioinformatics/btr260 ↗
47. 10.1038/s41587-020-0546-810.1038/s41587-020-0546-8 ↗
48. 10.7892/boris.12637110.7892/boris.126371 ↗
49. 10.1093/nar/gkl25310.1093/nar/gkl253 ↗
50. Sanner M. F. · J. Mol. Graphics Modell. · 1999 · 17 · 57
51. 10.1039/b300845m10.1039/b300845m ↗
52. 10.1093/nar/gkaa73810.1093/nar/gkaa738 ↗
53. 10.1021/ja062791w10.1021/ja062791w ↗
54. 10.1006/jmbi.2001.444710.1006/jmbi.2001.4447 ↗
55. 10.1093/nar/26.24.564410.1093/nar/26.24.5644 ↗
56. 10.1110/ps.0498370510.1110/ps.04983705 ↗
57. 10.1021/acs.jcim.5b0055910.1021/acs.jcim.5b00559 ↗
58. Schrodinger, L. L. C · The PyMOL Molecular Graphics System · 2015
59. 10.1093/nar/gkaa107410.1093/nar/gkaa1074 ↗
60. 10.2210/pdb3olj/pdb10.2210/pdb3olj/pdb ↗
61. 10.1021/jp200418j10.1021/jp200418j ↗
62. 10.1016/j.dyepig.2020.10886010.1016/j.dyepig.2020.108860 ↗